Form 4: Organogenesis Holdings Inc. CEO Awarded Stock Options and Restricted Stock Units

Gary S. Gillheeney, President and CEO of Organogenesis Holdings Inc., received stock options and restricted stock units (RSUs) on February 19, 2025.

Summary

• Gary S. Gillheeney, the President and CEO of Organogenesis Holdings Inc., filed a Form 4 on February 21, 2025.
• The filing reports changes in his beneficial ownership of the company's securities.
• On February 19, 2025, Gillheeney was granted 708,215 shares of Class A Common Stock as restricted stock units (RSUs).
• These RSUs vest in equal annual installments over four years, starting February 15, 2025.
• He was also granted a stock option to purchase 732,596 shares of Class A Common Stock at an exercise price of $3.53.
• This option becomes exercisable in equal annual installments over four years, beginning February 15, 2025.
• Following these transactions, Gillheeney directly owns 3,515,323 shares of Class A Common Stock and 732,596 stock options.
• The stock options expire on February 19, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity compensation is a standard practice and suggests confidence in the company's future performance, but it doesn't provide any groundbreaking news.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule of four years encourages long-term commitment from the CEO.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for CEOs in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of four years is also a typical arrangement to ensure long-term commitment.
• Comparable companies such as Vericel Corporation and Athersys often utilize similar equity-based compensation packages for their executives.

Stakeholder Impact

• The grant of equity compensation to the CEO could have a positive impact on shareholders by aligning his interests with theirs.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Organogenesis Holdings Inc., Gary S. Gillheeney, stock options, restricted stock units, RSUs, Form 4, beneficial ownership, equity incentive plan, Class A Common Stock